WEBVTT 00:00:00.000 --> 00:00:02.980 Welcome to the Deep Dive. Today we're tackling 00:00:02.980 --> 00:00:05.120 a medication that many of you might have encountered, 00:00:05.440 --> 00:00:07.259 either personally or maybe through someone you 00:00:07.259 --> 00:00:10.939 know, glipicide. Yeah, it's definitely one of 00:00:10.939 --> 00:00:12.859 the common ones. It is. It's a really common 00:00:12.859 --> 00:00:15.880 and, well, relatively affordable second generation 00:00:15.880 --> 00:00:18.879 sulfonylurea drug used to manage type 2 diabetes. 00:00:19.100 --> 00:00:23.460 That's right. Glipicide primarily works by encouraging 00:00:23.460 --> 00:00:26.420 the pancreas to release more insulin and also 00:00:26.670 --> 00:00:28.910 by making the body's tissues more responsive 00:00:28.910 --> 00:00:30.940 to the insulin that's already there. Which makes 00:00:30.940 --> 00:00:33.380 it super relevant for a deep dive, right? Yeah. 00:00:33.500 --> 00:00:36.240 It's wide use, the affordability factor. Exactly. 00:00:36.840 --> 00:00:38.939 And potential repurposing, market stuff, lots 00:00:38.939 --> 00:00:41.600 to unpack. It's widespread use in treating type 00:00:41.600 --> 00:00:43.920 2 diabetes makes it a really interesting subject 00:00:43.920 --> 00:00:46.759 for us to explore in depth. Absolutely. And for 00:00:46.759 --> 00:00:48.679 this deep dive, we've pulled together a pretty 00:00:48.679 --> 00:00:51.479 comprehensive set of sources. We're looking at, 00:00:51.500 --> 00:00:53.979 well, everything, really. Like what specifically? 00:00:54.079 --> 00:00:56.179 OK, so we've got a news release from the Washington 00:00:56.179 --> 00:00:58.859 State Attorney General's office, an EMA assessment 00:00:58.859 --> 00:01:03.039 report on a related drug, Dapocliflozin, the 00:01:03.039 --> 00:01:05.219 essential medicines list from Bello National 00:01:05.219 --> 00:01:08.579 Hospital. A study comparing metformin and glipicide 00:01:08.579 --> 00:01:11.799 on cardiovascular outcomes, info from the Mayo 00:01:11.799 --> 00:01:16.819 Clinic, the FDA label for Glutrol XL, a Google 00:01:16.819 --> 00:01:19.620 patents entry about a new way to synthesize glipicide. 00:01:20.079 --> 00:01:23.260 patient information from Pfizer, FDA guidelines 00:01:23.260 --> 00:01:25.980 on manufacturing APIs. Right, the DMP stuff. 00:01:26.099 --> 00:01:29.260 Yeah, exactly. A recall notice from Singapore's 00:01:29.260 --> 00:01:31.920 Health Sciences Authority. A StatPearls article 00:01:31.920 --> 00:01:36.040 on sulfonylureas. A market analysis, a consensus 00:01:36.040 --> 00:01:38.180 statement from the Gulf Cooperation Council. 00:01:38.260 --> 00:01:41.140 Wow, quite the list. An article discussing potentially 00:01:41.140 --> 00:01:43.540 repurposing gliposide for brain disorders. And 00:01:43.540 --> 00:01:46.120 finally, a market research report specifically 00:01:46.120 --> 00:01:48.840 on gliposide itself. So our mission today is 00:01:48.840 --> 00:01:50.900 to really unpack the whole story of gliposide. 00:01:51.159 --> 00:01:53.819 We want to explore its origins, how it came to 00:01:53.819 --> 00:01:56.120 be, how it actually works in the body to manage 00:01:56.120 --> 00:01:58.739 diabetes, the journey it's taken through regulatory 00:01:58.739 --> 00:02:02.319 systems, and the significant impact it's had 00:02:02.319 --> 00:02:04.340 both on health care and the economy. Okay, let's 00:02:04.340 --> 00:02:06.140 get started then. Looking at its history and 00:02:06.140 --> 00:02:07.799 how it's used, we know it's second -generation 00:02:07.799 --> 00:02:10.219 sulfonylurea. What does that actually tell us 00:02:10.219 --> 00:02:12.439 about its place in the evolution of these diabetes 00:02:12.439 --> 00:02:14.719 meds? Well, sulfonylureas as a class, they've 00:02:14.719 --> 00:02:17.120 been around for quite a while. Glipposide represents 00:02:17.120 --> 00:02:19.300 a sort of later stage in their development, hence 00:02:19.300 --> 00:02:22.180 second generation. It's primary role, as we said, 00:02:22.539 --> 00:02:25.599 is managing type 2 diabetes. It nudges the pancreas 00:02:25.599 --> 00:02:27.979 to produce more insulin and helps the body use 00:02:27.979 --> 00:02:30.280 that insulin better in tissues like muscle and 00:02:30.280 --> 00:02:33.539 fat. So it's directly tweaking the body's insulin 00:02:33.539 --> 00:02:35.639 system, which is obviously central to managing 00:02:35.639 --> 00:02:38.699 type 2 diabetes. Our Stat Pearls article mentioned 00:02:38.699 --> 00:02:41.060 a couple of other sulfonylureas, tulbutamide 00:02:41.060 --> 00:02:44.300 and glyburide. How does glipicide stack up against 00:02:44.300 --> 00:02:47.159 these older relatives? That's a good comparison. 00:02:47.419 --> 00:02:49.479 Tulbutamide, it's characterized as shorter acting. 00:02:49.740 --> 00:02:52.139 Usually comes in 500 -milligram pablets, and 00:02:52.139 --> 00:02:54.240 dosages can go from 1 ,000 milligrams up to 3 00:02:54.240 --> 00:02:56.860 ,000 milligrams daily, often split. OK, shorter 00:02:56.860 --> 00:02:59.590 acting. And glybride. Glybride, on the other 00:02:59.590 --> 00:03:02.250 hand, has a longer duration of action. It typically 00:03:02.250 --> 00:03:04.430 starts at a lower dose, maybe 2 .5 milligrams 00:03:04.430 --> 00:03:06.830 to 5 milligrams once a day, maxing out around 00:03:06.830 --> 00:03:09.949 20 milligrams. Ah, so longer lasting. Exactly. 00:03:10.370 --> 00:03:12.430 And an important thing with glybride is how it 00:03:12.430 --> 00:03:14.710 interacts with kidney function. Generally, the 00:03:14.710 --> 00:03:17.729 dose might need reducing if the EGFR, that's 00:03:17.729 --> 00:03:20.069 the estimated glomerular filtration rate, is 00:03:20.069 --> 00:03:22.490 between 60 and 90. Right, the kidney clearance 00:03:22.490 --> 00:03:24.849 measure. Yeah. And it's often avoided completely 00:03:24.849 --> 00:03:28.289 if the EGFR drops below 60. So these differences 00:03:28.289 --> 00:03:30.250 in how long they work, how they're cleared by 00:03:30.250 --> 00:03:33.069 the body, they're really key considerations for 00:03:33.069 --> 00:03:35.830 doctors picking the right medication. Those differences, 00:03:36.129 --> 00:03:39.229 especially the kidney thing for glybride, really 00:03:39.229 --> 00:03:41.830 show that even within the same drug class, things 00:03:41.830 --> 00:03:44.240 aren't always simple, are they? Not at all. Now, 00:03:44.419 --> 00:03:46.840 thinking bigger picture, we have newer classes 00:03:46.840 --> 00:03:50.219 of diabetes meds now. That EMA assessment report 00:03:50.219 --> 00:03:53.439 for dipocliflasin, an SGLT2 inhibitor, gives 00:03:53.439 --> 00:03:55.919 us some context. It even mentioned a study directly 00:03:55.919 --> 00:03:58.580 comparing it to glipizide. What was the key finding 00:03:58.580 --> 00:04:01.599 there? What's particularly interesting is the 00:04:01.599 --> 00:04:03.539 difference in the risk of hypoglycemia, you know, 00:04:03.680 --> 00:04:06.439 low blood sugar. Ah, yes. A common concern with 00:04:06.439 --> 00:04:10.020 sulfonylureous. Very much so. In a study detailed 00:04:10.020 --> 00:04:13.060 in that EMA report, when they compared depaglophosin 00:04:13.060 --> 00:04:15.599 plus metformin to glyphoside plus metformin, 00:04:15.900 --> 00:04:19.139 the rate of hypoglycemia was way lower in the 00:04:19.139 --> 00:04:21.439 depaglophosin group. How much lower are we talking? 00:04:21.519 --> 00:04:25.100 Only about 3 % compared to a much higher 40 % 00:04:25.100 --> 00:04:28.259 in the glucoside group. 40 %? Wow, that's substantial. 00:04:28.519 --> 00:04:30.720 It really is. It underscores one of the main 00:04:30.720 --> 00:04:33.279 challenges with drugs like glyphoside, that potential 00:04:33.279 --> 00:04:36.180 for causing low blood sugar. The reason for the 00:04:36.180 --> 00:04:38.089 difference is really down to how they work. How 00:04:38.089 --> 00:04:41.410 so? Well, SGLT2 inhibitors like dipaglofazin, 00:04:41.410 --> 00:04:44.089 they mainly work in the kidneys, helping remove 00:04:44.089 --> 00:04:47.240 excess glucose through urine. It's a less direct 00:04:47.240 --> 00:04:49.980 impact on insulin release compared to the sulfonylureous. 00:04:50.240 --> 00:04:52.100 Right. Different mechanism entirely. That's a 00:04:52.100 --> 00:04:55.019 very significant difference in risk. The EMA 00:04:55.019 --> 00:04:58.040 report also mentioned ongoing phase 3B studies 00:04:58.040 --> 00:05:00.839 looking at depagliflozin in heart failure patients. 00:05:01.100 --> 00:05:03.379 Now, that's not directly about gliposide, but 00:05:03.379 --> 00:05:06.300 it suggests a trend, doesn't it? Research exploring 00:05:06.300 --> 00:05:09.160 broader cardiovascular benefits in diabetes drugs? 00:05:09.259 --> 00:05:11.420 It does. Is that an area where sulfonylureous 00:05:11.420 --> 00:05:13.920 have a similar kind of profile? That's a bit 00:05:13.920 --> 00:05:16.430 of a nuanced area. The consensus statement from 00:05:16.430 --> 00:05:18.730 the Gulf Cooperation Council, it touches on this 00:05:18.730 --> 00:05:21.250 long debated topic of cardiovascular safety with 00:05:21.250 --> 00:05:24.029 sulfonylureas. Despite them being used for so 00:05:24.029 --> 00:05:26.509 long. Exactly. They referenced the Carolina trial. 00:05:26.949 --> 00:05:29.790 That compared glampyride, another sulfonylurea, 00:05:29.970 --> 00:05:33.050 to lenaglyptin, a DPP4 inhibitor on cardiovascular 00:05:33.050 --> 00:05:36.189 safety. And it found glampyride was non -inferior. 00:05:36.550 --> 00:05:38.990 Meaning it wasn't worse than the newer drug, 00:05:39.269 --> 00:05:42.220 heartwise. Precisely. which provided some reassurance 00:05:42.220 --> 00:05:44.959 for doctors. However, that same GCC statement 00:05:44.959 --> 00:05:47.720 also acknowledges the growing evidence for actual 00:05:47.720 --> 00:05:49.899 cardioprotective benefits from newer classes, 00:05:50.399 --> 00:05:53.879 like the SGLT2 inhibitors and GLP1 receptor agonists. 00:05:54.120 --> 00:05:55.959 Right, so those might be preferred now, especially 00:05:55.959 --> 00:05:57.779 for patients who already have heart or kidney 00:05:57.779 --> 00:05:59.920 issues. That's likely the direction things are 00:05:59.920 --> 00:06:02.019 heading, yes. Those additional benefits are becoming 00:06:02.019 --> 00:06:04.620 a bigger factor in treatment decisions. So while 00:06:04.620 --> 00:06:07.199 drugs like glipicide are still valuable tools, 00:06:07.480 --> 00:06:09.620 the whole landscape is definitely shifting with 00:06:09.620 --> 00:06:13.180 these newer therapies offering more. Now, switching 00:06:13.180 --> 00:06:15.699 gears completely. One of our sources, an article, 00:06:15.899 --> 00:06:19.120 talks about the, well, entreating idea of repurposing 00:06:19.120 --> 00:06:21.920 glipicide for brain disorders. That sounds like 00:06:21.920 --> 00:06:24.060 quite a leap from diabetes. It is a fascinating 00:06:24.060 --> 00:06:26.870 area, isn't it? The article highlights a study 00:06:26.870 --> 00:06:29.269 suggesting that because Glipposide stimulates 00:06:29.269 --> 00:06:32.310 insulin signaling, which is also vital for how 00:06:32.310 --> 00:06:35.250 brain cells manage energy, it might potentially 00:06:35.250 --> 00:06:38.110 have uses beyond diabetes. For more logical conditions. 00:06:38.290 --> 00:06:40.410 Potentially, yes. For certain ones. The research 00:06:40.410 --> 00:06:42.569 is still pretty early stage, obviously. But it 00:06:42.569 --> 00:06:45.250 raises this exciting possibility that drugs we 00:06:45.250 --> 00:06:47.470 already have might have hidden talents for treating 00:06:47.470 --> 00:06:49.930 a wider range of diseases. It really does. OK, 00:06:49.970 --> 00:06:51.410 this is where it gets really interesting for 00:06:51.410 --> 00:06:54.620 me. How do we actually make Glipposide? We have 00:06:54.620 --> 00:06:56.819 that Google patents entry hinting at a novel 00:06:56.819 --> 00:06:59.660 synthesis route. What can you tell us about manufacturing 00:06:59.660 --> 00:07:01.740 these drugs in general and what might be novel 00:07:01.740 --> 00:07:04.480 here? Well, that Google patents entry suggests 00:07:04.480 --> 00:07:08.519 there's still active work on finding, you know, 00:07:08.699 --> 00:07:10.699 better, maybe more efficient or cost effective 00:07:10.699 --> 00:07:13.860 ways to synthesize glyphoside. Even for an established 00:07:13.860 --> 00:07:16.399 drug. Absolutely. While the specifics of that 00:07:16.399 --> 00:07:18.860 novel route would be in the patent details, the 00:07:18.860 --> 00:07:21.060 general manufacturing of active pharmaceutical 00:07:21.060 --> 00:07:24.529 ingredients, APIs like glyphoside is super tightly 00:07:24.529 --> 00:07:26.970 controlled. By the FDA and other agencies, right? 00:07:27.110 --> 00:07:30.529 Yes. The FDA's Q7 Good Manufacturing Practice 00:07:30.529 --> 00:07:33.550 or GMP guidelines are key. They provide the whole 00:07:33.550 --> 00:07:35.870 framework for ensuring the quality and safety 00:07:35.870 --> 00:07:38.329 of these ingredients. It's all about strict quality 00:07:38.329 --> 00:07:41.110 control at every single step, meticulous record 00:07:41.110 --> 00:07:43.629 keeping. Accountability. Exactly. And ultimately 00:07:43.629 --> 00:07:46.170 making sure the final product is safe and actually 00:07:46.170 --> 00:07:48.189 works for patients. OK. So what are some of the 00:07:48.189 --> 00:07:50.730 big themes within those GMP guidelines? What 00:07:50.730 --> 00:07:53.189 do they cover? Several critical things. First, 00:07:53.269 --> 00:07:55.660 they really stress having qualified people and 00:07:55.660 --> 00:07:58.100 maintaining very high levels of hygiene in the 00:07:58.100 --> 00:08:01.459 manufacturing facility. Seems basic, but it's 00:08:01.459 --> 00:08:03.560 crucial. Makes sense. Contamination would be 00:08:03.560 --> 00:08:07.420 bad. Very bad. Second, they mandate meticulous 00:08:07.420 --> 00:08:10.220 control over all the paperwork. Specifications 00:08:10.220 --> 00:08:13.399 for raw materials, the finished API, detailed 00:08:13.399 --> 00:08:16.040 manufacturing procedures, comprehensive records 00:08:16.040 --> 00:08:19.160 for every single batch. Traceability again. Yes. 00:08:19.600 --> 00:08:22.680 And with specific time limits for process stages 00:08:22.680 --> 00:08:25.379 and how long records need to be kept. Got it. 00:08:25.759 --> 00:08:28.259 What about the quality of the actual drug substance 00:08:28.259 --> 00:08:31.920 itself? The guidelines detail the need for established 00:08:31.920 --> 00:08:34.740 quality specifications for the API. This means 00:08:34.740 --> 00:08:37.200 rigorous testing to control impurities, both 00:08:37.200 --> 00:08:40.799 chemical ones and microbiological ones. To make 00:08:40.799 --> 00:08:43.340 sure it's pure and safe. Correct. Plus, proper 00:08:43.340 --> 00:08:45.159 handling and testing of reference standards, 00:08:45.559 --> 00:08:47.679 those are the ultra -pure samples used to calibrate 00:08:47.679 --> 00:08:49.519 equipment that's essential for accurate quality 00:08:49.519 --> 00:08:51.639 control. And the tests themselves need to be 00:08:51.639 --> 00:08:53.679 reliable. Absolutely. The analytical methods 00:08:53.679 --> 00:08:56.120 used for testing must be validated to prove they're 00:08:56.120 --> 00:08:58.139 accurate and dependable. And if any changes are 00:08:58.139 --> 00:09:00.240 made to the manufacturing process. Like that 00:09:00.240 --> 00:09:03.059 potential new synthesis route? Exactly. There 00:09:03.059 --> 00:09:05.620 have to be established change control procedures 00:09:05.620 --> 00:09:08.919 to assess the impact on quality. There are also 00:09:08.919 --> 00:09:11.299 strict protocols for handling any materials that 00:09:11.299 --> 00:09:13.600 don't meet the specs rejection, or sometimes 00:09:13.600 --> 00:09:16.679 reprocessing under strict conditions. So a really 00:09:16.679 --> 00:09:19.620 robust system of checks and balances. What about 00:09:19.620 --> 00:09:22.759 the final steps? Getting the API ready to be 00:09:22.759 --> 00:09:25.399 put into pills or tablets? The guidelines cover 00:09:25.399 --> 00:09:28.200 that too. packaging, labeling, distribution of 00:09:28.200 --> 00:09:31.340 the API. And throughout all these stages, sticking 00:09:31.340 --> 00:09:33.460 to fundamental quality management principles 00:09:33.460 --> 00:09:36.820 is paramount. Finally, stability is crucial. 00:09:36.960 --> 00:09:39.440 How long it lasts on the shelf? Basically, yes. 00:09:39.820 --> 00:09:41.720 Manufacturers have to do studies to ensure the 00:09:41.720 --> 00:09:44.519 API stays potent and safe over its intended shelf 00:09:44.519 --> 00:09:46.919 life, assuming it's stored correctly. That paints 00:09:46.919 --> 00:09:49.419 a really clear picture of the rigorous standards 00:09:49.419 --> 00:09:52.840 involved. Okay, let's shift focus now to glipisides 00:09:52.840 --> 00:09:55.139 regulatory journey. We know it's FDA approved. 00:09:55.539 --> 00:09:57.740 What do our sources tell us about its path and 00:09:57.740 --> 00:09:59.919 any maybe challenges or interesting points along 00:09:59.919 --> 00:10:02.759 the way? Well, as we noted, it's an FDA approved 00:10:02.759 --> 00:10:06.490 second -gen sulfonylurea. If we look at the FDA 00:10:06.490 --> 00:10:09.549 label info for Glucatrol XL, that's Pfizer's 00:10:09.549 --> 00:10:13.210 extended release version, we see regulatory oversight 00:10:13.210 --> 00:10:16.289 continuing even for established drugs. How so? 00:10:16.370 --> 00:10:18.870 For instance, a supplemental new drug application, 00:10:19.070 --> 00:10:22.769 an SNDA, for a 2 .5 milligram dose of Glucatrol 00:10:22.769 --> 00:10:26.730 XL was approved way back in August 1999. So adding 00:10:26.730 --> 00:10:29.409 a new strength required approval. Exactly. It 00:10:29.409 --> 00:10:31.789 shows that even seemingly small changes need 00:10:31.789 --> 00:10:34.250 regulatory review. The approval letter itself 00:10:34.320 --> 00:10:36.899 mentions that this 2 .5 milligram tablet met 00:10:36.899 --> 00:10:39.480 the USP standards United States pharmacopeia, 00:10:39.519 --> 00:10:41.620 and it was the manufacturing sites involved back 00:10:41.620 --> 00:10:44.950 then. Even for a known drug, the regulatory story 00:10:44.950 --> 00:10:46.830 keeps evolving. That's a good reminder. Oversight 00:10:46.830 --> 00:10:48.590 is continuous, not just a one -off approval. 00:10:48.990 --> 00:10:50.649 But on the flip side, we also have that recall 00:10:50.649 --> 00:10:52.669 notice from Singapore about a glipizide product. 00:10:52.710 --> 00:10:54.970 What does that tell us? Yeah, the recall of Sandalikon 00:10:54.970 --> 00:10:57.529 tablet 5 milligrams in Singapore just in May 00:10:57.529 --> 00:10:59.950 2024. That really highlights the crucial role 00:10:59.950 --> 00:11:01.710 of post -market surveillance and quality control. 00:11:01.850 --> 00:11:03.730 What went wrong? The recall happened because 00:11:03.730 --> 00:11:06.730 several batches failed a dissolution test. Basically, 00:11:06.830 --> 00:11:09.490 that test checks if the pill breaks down properly 00:11:09.490 --> 00:11:12.090 in the body to release the medication. So if 00:11:12.090 --> 00:11:14.070 it fails, the patient might not get the right 00:11:14.070 --> 00:11:16.370 dose. Precisely. They might get too little or 00:11:16.370 --> 00:11:18.250 maybe too much too quickly depending on the failure. 00:11:18.730 --> 00:11:20.950 It just underscores the ongoing responsibility 00:11:20.950 --> 00:11:23.830 of manufacturers and regulators to ensure approved 00:11:23.830 --> 00:11:26.269 meds keep meeting quality standards throughout 00:11:26.269 --> 00:11:28.929 their life on the market. Right. And then we 00:11:28.929 --> 00:11:31.370 have this expanded lawsuit from the Washington 00:11:31.370 --> 00:11:34.149 state AG and others about alleged price fixing 00:11:34.149 --> 00:11:36.710 in the generic drug industry. Now, Glicoside 00:11:36.710 --> 00:11:38.889 isn't specifically named in the bit we have, 00:11:38.889 --> 00:11:42.090 but it seems relevant context, doesn't it? Especially 00:11:42.090 --> 00:11:44.570 concerning the pricing of these important generic 00:11:44.570 --> 00:11:47.409 meds. Absolutely relevant context. The lawsuit 00:11:47.409 --> 00:11:50.690 alleges this widespread conspiracy among 18 generic 00:11:50.690 --> 00:11:53.889 companies across 15 different drugs. The goal, 00:11:54.049 --> 00:11:56.470 allegedly, was to artificially inflate prices 00:11:56.470 --> 00:11:59.470 and squash competition. And the price increases 00:11:59.470 --> 00:12:01.929 mentioned were huge. Some were reportedly over 00:12:01.929 --> 00:12:04.870 a thousand percent, which is just staggering. 00:12:05.190 --> 00:12:08.090 It really illustrates the potential for market 00:12:08.090 --> 00:12:10.110 manipulation within the generic pharma sector. 00:12:10.360 --> 00:12:13.019 So this legal action highlights the need for 00:12:13.019 --> 00:12:15.559 a regulatory scrutiny and enforcement to protect 00:12:15.559 --> 00:12:18.960 consumers, ensure fair pricing, especially for 00:12:18.960 --> 00:12:21.899 essential generics like diabetes drugs. Exactly. 00:12:22.080 --> 00:12:24.340 Even if Glyphosate itself wasn't the focus of 00:12:24.340 --> 00:12:26.740 this specific legal action mentioned in our source, 00:12:27.120 --> 00:12:29.159 it's part of that broader environment. OK, so 00:12:29.159 --> 00:12:31.659 from initial approvals and new formulations to 00:12:31.659 --> 00:12:34.480 quality recalls and legal battles over pricing, 00:12:34.960 --> 00:12:36.899 the regulatory world for a drug like Glyphoside 00:12:36.899 --> 00:12:40.120 is complex and always moving. Let's pivot now 00:12:40.120 --> 00:12:43.100 to the economic side. Being a generic, Glyphoside 00:12:43.100 --> 00:12:45.480 must play a big role in the cost and accessibility 00:12:45.480 --> 00:12:48.259 of diabetes care. Our market analysis gives some 00:12:48.259 --> 00:12:51.039 clues here. Yes, the global market just for sulfonylureous 00:12:51.039 --> 00:12:53.159 Glyphoside class is pretty substantial. It's 00:12:53.159 --> 00:12:58.080 projected to hit USD 7 .25 billion by 2032. 7 00:12:58.080 --> 00:13:00.779 .25 billion, that's significant. It is, with 00:13:00.779 --> 00:13:03.080 a compound annual growth rate forecasted around 00:13:03.080 --> 00:13:06.539 3 .19%. And this growth is largely driven by, 00:13:06.539 --> 00:13:09.000 well, the unfortunate rise in global obesity 00:13:09.000 --> 00:13:11.679 and type 2 diabetes rates. And rising healthcare 00:13:11.679 --> 00:13:14.720 spending generally. That too, plus an aging global 00:13:14.720 --> 00:13:18.120 population, all contribute. And gliposide, being 00:13:18.120 --> 00:13:21.419 a widely used sulfonylurea available as a generic. 00:13:21.840 --> 00:13:24.519 It must be a huge part of this market, especially 00:13:24.519 --> 00:13:26.779 for keeping treatment affordable. Absolutely 00:13:26.779 --> 00:13:30.100 huge. Generic glipizide is a key factor driving 00:13:30.100 --> 00:13:32.759 down the cost of diabetes treatment. That makes 00:13:32.759 --> 00:13:35.779 it way more accessible for more patients, especially 00:13:35.779 --> 00:13:37.960 in regions with tighter health care budgets. 00:13:38.279 --> 00:13:41.139 Who are the main companies involved? The market 00:13:41.139 --> 00:13:43.419 analysis points to several key players. You've 00:13:43.419 --> 00:13:46.320 got major generic manufacturers, think Amniel, 00:13:46.500 --> 00:13:49.940 Dr. Reddy's, Teva, Sun Pharma, Ourobindo. The 00:13:49.940 --> 00:13:52.600 big generic names. Right. But also the original 00:13:52.600 --> 00:13:54.539 developers and manufacturers like Pfizer and 00:13:54.539 --> 00:13:57.240 Novartis are still in the mix. This blend of 00:13:57.240 --> 00:13:59.879 generic and branded competition shapes the market 00:13:59.879 --> 00:14:02.350 dynamics and the pricing. Interesting that the 00:14:02.350 --> 00:14:04.870 originators are still major players. Geographically, 00:14:05.049 --> 00:14:06.830 where is the biggest demand for sulfonylureas 00:14:06.830 --> 00:14:09.370 like glipicide? Currently, North America and 00:14:09.370 --> 00:14:11.549 Europe are expected to be the dominant markets. 00:14:11.909 --> 00:14:13.889 That's likely due to their established health 00:14:13.889 --> 00:14:16.590 care infrastructure and, frankly, higher rates 00:14:16.590 --> 00:14:19.090 of diagnosed diabetes. But growth is happening 00:14:19.090 --> 00:14:22.159 elsewhere. Definitely. The research points to 00:14:22.159 --> 00:14:24.340 rapidly increasing demand in the Asia -Pacific 00:14:24.340 --> 00:14:27.379 region, particularly India and China. That's 00:14:27.379 --> 00:14:30.080 driven by the huge rise in diabetes cases there, 00:14:30.320 --> 00:14:32.740 plus improving access to health care. Makes sense. 00:14:33.000 --> 00:14:34.740 And there's also that specific market research 00:14:34.740 --> 00:14:37.620 report mentioned projecting trends just for glipiside 00:14:37.620 --> 00:14:41.120 tablets up to 2031. It considers the ongoing 00:14:41.120 --> 00:14:44.279 impact of generics and any potential tech advances 00:14:44.279 --> 00:14:48.070 in, say, drug delivery. So really, a global story. 00:14:48.210 --> 00:14:50.409 Established markets, rapidly expanding ones, 00:14:50.990 --> 00:14:54.149 all relying on this medication. Okay, finally, 00:14:54.350 --> 00:14:56.750 let's think about the cultural influence. As 00:14:56.750 --> 00:14:59.720 such a widely used, affordable drug, Glyphoside 00:14:59.720 --> 00:15:01.919 must have had a pretty big impact on people's 00:15:01.919 --> 00:15:03.820 lives and health care systems. Without a doubt. 00:15:03.980 --> 00:15:06.240 I mean, given how common it is and its relative 00:15:06.240 --> 00:15:09.000 affordability, Glyphoside has likely been a cornerstone 00:15:09.000 --> 00:15:11.460 of diabetes management for a vast number of people 00:15:11.460 --> 00:15:13.779 globally. And its inclusion on essential medicines 00:15:13.779 --> 00:15:16.120 lists, like the one from Ballot National Hospital. 00:15:16.440 --> 00:15:18.500 That really underlines its importance, doesn't 00:15:18.500 --> 00:15:21.639 it? It shows it's seen as a fundamental medication 00:15:21.639 --> 00:15:25.639 for treating a common chronic condition within 00:15:25.639 --> 00:15:29.090 basic health care systems. It's a testament to 00:15:29.090 --> 00:15:31.309 its established effectiveness and accessibility. 00:15:31.809 --> 00:15:33.889 And that research we mentioned about potentially 00:15:33.889 --> 00:15:36.830 repurposing it for brain disorders, even if it's 00:15:36.830 --> 00:15:39.370 early days, that could eventually shift how we 00:15:39.370 --> 00:15:41.090 think about this drug entirely, couldn't it? 00:15:41.309 --> 00:15:45.190 Precisely. Beyond just a diabetes drug, the StatPearls 00:15:45.190 --> 00:15:47.129 article also brings up the collaborative nature 00:15:47.129 --> 00:15:49.919 of diabetes care. It's not just doctors. Right. 00:15:50.000 --> 00:15:52.600 It involves pharmacists, educators, the patients 00:15:52.600 --> 00:15:54.879 themselves. Exactly. Pharmacists, for instance, 00:15:55.080 --> 00:15:57.899 play a crucial role. They review medication histories, 00:15:58.320 --> 00:16:00.059 make sure patients understand how to take meds 00:16:00.059 --> 00:16:02.740 correctly, monitor adherence, suggest adjustments, 00:16:03.500 --> 00:16:05.860 all directly involving drugs like glipizide. 00:16:06.360 --> 00:16:08.279 And patient education is key too, especially 00:16:08.279 --> 00:16:10.500 with that hypoglycemia risk we talked about. 00:16:10.960 --> 00:16:14.090 Absolutely. That emphasis on teaching patients 00:16:14.090 --> 00:16:16.110 how to manage low blood schizur, often called 00:16:16.110 --> 00:16:19.110 the Rule of 15, illustrates how self -management 00:16:19.110 --> 00:16:21.370 strategies have become really integrated into 00:16:21.370 --> 00:16:23.929 the sort of cultural understanding of diabetes 00:16:23.929 --> 00:16:26.389 care. And glipizide is one of those meds where 00:16:26.389 --> 00:16:29.419 that education is particularly vital. So Glipposide 00:16:29.419 --> 00:16:31.820 is more than just a chemical compound. It's really 00:16:31.820 --> 00:16:34.620 woven into how we understand, manage, and live 00:16:34.620 --> 00:16:37.159 with a widespread chronic disease on a global 00:16:37.159 --> 00:16:40.159 scale. Indeed. Its story touches on scientific 00:16:40.159 --> 00:16:42.799 discovery, those rigorous manufacturing processes, 00:16:43.480 --> 00:16:46.200 constant regulatory oversight, significant economic 00:16:46.200 --> 00:16:49.620 forces, and profound impact on healthcare practices 00:16:49.620 --> 00:16:52.279 and the lives of countless patients. So to wrap 00:16:52.279 --> 00:16:55.019 up our deep dive into Glipposide. We've traced 00:16:55.019 --> 00:16:57.899 its journey as a reliable, though not without 00:16:57.899 --> 00:17:00.480 potential risks like hypoglycemia, but still 00:17:00.480 --> 00:17:02.559 a workhorse medication for managing diabetes. 00:17:02.679 --> 00:17:05.059 Yeah, a mainstay for many years. We've explored 00:17:05.059 --> 00:17:07.579 the complexities of how it's made and the regulatory 00:17:07.579 --> 00:17:10.240 world it navigates. We've highlighted its substantial 00:17:10.240 --> 00:17:12.920 economic footprint, largely thanks to generic 00:17:12.920 --> 00:17:15.059 availability. Which makes a huge difference in 00:17:15.059 --> 00:17:17.670 access. And we've even touched on those intriguing 00:17:17.670 --> 00:17:20.109 possibilities for its future, maybe treating 00:17:20.109 --> 00:17:22.529 conditions beyond diabetes. And as we've seen, 00:17:22.690 --> 00:17:24.930 Glipposide's story is really a powerful illustration 00:17:24.930 --> 00:17:28.410 of the broader pharmaceutical world. It showcases 00:17:28.410 --> 00:17:31.009 that constant interplay between scientific innovation, 00:17:31.710 --> 00:17:34.250 the crucial need for accessibility and affordability. 00:17:34.289 --> 00:17:36.769 The importance of quality control and safety. 00:17:37.549 --> 00:17:39.970 And that ongoing search for new applications 00:17:39.970 --> 00:17:42.430 for the therapeutic tools we already have in 00:17:42.430 --> 00:17:44.650 our toolkit. Final thought for you, the listener. 00:17:45.230 --> 00:17:47.670 Considering Glipposide's long -standing effectiveness 00:17:47.670 --> 00:17:50.789 and affordability, but also seeing the rise of 00:17:50.789 --> 00:17:52.809 newer diabetes therapies with different mechanisms 00:17:52.809 --> 00:17:55.730 and maybe extra benefits, what do you foresee 00:17:55.730 --> 00:17:58.789 as the enduring role for medications like Glipposide 00:17:58.789 --> 00:18:02.569 in the future of diabetes care? And thinking 00:18:02.569 --> 00:18:05.269 about that potential for drug repurposing becoming 00:18:05.269 --> 00:18:08.309 more common. What are the broader implications 00:18:08.309 --> 00:18:11.309 for how we think about and maybe utilize the 00:18:11.309 --> 00:18:13.180 medicines we already have? It's certainly a lot 00:18:13.180 --> 00:18:14.799 to consider. Thanks for taking this deep dive 00:18:14.799 --> 00:18:15.319 with us.